Cancer Suicide Gene Therapy with TK.007
Standard
Cancer Suicide Gene Therapy with TK.007. / Hossain, Jubayer A; Riecken, Kristoffer; Miletic, Hrvoje; Fehse, Boris.
in: Methods Mol Biol, Jahrgang 1895, 2019, S. 11-26.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Cancer Suicide Gene Therapy with TK.007
AU - Hossain, Jubayer A
AU - Riecken, Kristoffer
AU - Miletic, Hrvoje
AU - Fehse, Boris
PY - 2019
Y1 - 2019
N2 - Cancer is a devastating disease characterized by uncontrolled and aggressive cell growth. Suicide gene therapy (SGT) facilitating induction of malignancy-specific cell death represents a novel therapeutic approach to treat cancer, which has been investigated in several cancer types with very promising results. In addition, SGT has been suggested as a safeguard in adoptive immunotherapy and regenerative-medicine settings. Generally, SGT consists of two steps-vector-mediated delivery of suicide genes into tumors and subsequent activation of the suicide mechanism, e.g., by administration of a specific prodrug. This chapter provides a framework of protocols for basic and translational research using the Herpes-simplex-virus thymidine kinase (HSV-TK)/ganciclovir (GCV) system, the most widely used suicide gene approach. The protocols provide standard guidelines for the preparation of high-titer third-generation lentiviral vectors encoding a genetically improved HSV-TK version known as TK.007 and its application in in vitro and in vivo treatment setups.
AB - Cancer is a devastating disease characterized by uncontrolled and aggressive cell growth. Suicide gene therapy (SGT) facilitating induction of malignancy-specific cell death represents a novel therapeutic approach to treat cancer, which has been investigated in several cancer types with very promising results. In addition, SGT has been suggested as a safeguard in adoptive immunotherapy and regenerative-medicine settings. Generally, SGT consists of two steps-vector-mediated delivery of suicide genes into tumors and subsequent activation of the suicide mechanism, e.g., by administration of a specific prodrug. This chapter provides a framework of protocols for basic and translational research using the Herpes-simplex-virus thymidine kinase (HSV-TK)/ganciclovir (GCV) system, the most widely used suicide gene approach. The protocols provide standard guidelines for the preparation of high-titer third-generation lentiviral vectors encoding a genetically improved HSV-TK version known as TK.007 and its application in in vitro and in vivo treatment setups.
KW - Journal Article
U2 - 10.1007/978-1-4939-8922-5_2
DO - 10.1007/978-1-4939-8922-5_2
M3 - SCORING: Journal article
C2 - 30539526
VL - 1895
SP - 11
EP - 26
JO - Methods Mol Biol
JF - Methods Mol Biol
SN - 1064-3745
ER -